title: Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial.
abstract: Tipifarnib (R115777) inhibits farnesylation of key proteins that modulate signaling pathways implicated in cell growth and proliferation, including members of the Ras and Rho families. It has broad-spectrum antiproliferative activity in vitro and in vivo. Clinical trials employing a continuous administration schedule have demonstrated dose-limiting neurotoxicity and myelosuppression. Preclinical studies have shown that intermittent oral administration can suppress tumor growth comparable to continuous administration. We conducted a National Cancer Institute-sponsored phase I trial to determine the feasibility of an intermittent dosing schedule of R115777 given orally twice daily on weeks 1 and 3 of a 28-day cycle in patients with malignant solid tumors. Starting dose was 300 mg twice daily (b.i.d.) with escalation by 300 mg b.i.d. increments over six dose levels to a maximum of 1800 mg b.i.d. Dose-limiting toxicity (DLT) was defined as any grade 3 or 4 non-hematologic toxicity, grade 4 thrombocytopenia, grade 4 neutropenia (ANC) with fever (38.3 degrees C or above) or a documented infection. Twenty-one patients with advanced solid tumors, all of whom had prior systemic therapy, were accrued. Grade 3 fatigue was dose limiting for two of three patients at the 900 mg b.i.d. dose level. Although no responses were seen, four of six patients with stable disease remained on study for at least a year (16, 17, 13 and 12 months) before developing progressive disease. Three of these prolonged stable disease patients had non-small cell lung cancer. We conclude that intermittent dosing of R115777 is feasible and tolerable. The recommended phase II dose is 600 mg orally b.i.d. on alternate weeks.
authors.affiliation: University of California, Davis Cancer Center, Sacramento, CA 95817, USA. primo.lara@ucdmc.ucdavis.edu
authors.forename: Primo N
authors.initials: PN
authors.lastname: Lara
authors.forename: Lisa Y
authors.initials: LY
authors.lastname: Law
authors.forename: John J
authors.initials: JJ
authors.lastname: Wright
authors.forename: Paul
authors.initials: P
authors.lastname: Frankel
authors.forename: Przemyslaw
authors.initials: P
authors.lastname: Twardowski
authors.forename: Heinz Josef
authors.initials: HJ
authors.lastname: Lenz
authors.forename: Derick H M
authors.initials: DH
authors.lastname: Lau
authors.forename: Tomoya
authors.initials: T
authors.lastname: Kawaguchi
authors.forename: Paul H
authors.initials: PH
authors.lastname: Gumerlock
authors.forename: James H
authors.initials: JH
authors.lastname: Doroshow
authors.forename: David R
authors.initials: DR
authors.lastname: Gandara
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D002140:California; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D017368:Protein Prenylation / Q000187:drug effects; D015363:Quinolones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D015363:Quinolones; C402769:tipifarnib